Rockwell Medical Inc (NASDAQ:RMTI) – Craig Hallum issued their Q2 2017 EPS estimates for Rockwell Medical in a report released on Wednesday. Craig Hallum analyst C. Haff forecasts that the company will earn ($0.10) per share for the quarter. Craig Hallum also issued estimates for Rockwell Medical’s Q3 2017 earnings at ($0.10) EPS, Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.39) EPS and FY2018 earnings at ($0.40) EPS.

Separately, Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, April 11th.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/05/15/rockwell-medical-inc-forecasted-to-post-q2-2017-earnings-of-0-10-per-share-rmti.html.

Shares of Rockwell Medical (NASDAQ:RMTI) opened at 6.63 on Monday. The firm’s market capitalization is $341.62 million. The firm’s 50-day moving average price is $7.14 and its 200-day moving average price is $6.36. Rockwell Medical has a one year low of $3.55 and a one year high of $10.58.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.09) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.09). Rockwell Medical had a negative return on equity of 33.60% and a negative net margin of 37.98%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $12.66 million. During the same period last year, the business posted ($0.10) EPS. The business’s revenue was up 7.4% compared to the same quarter last year.

In related news, Director Kenneth L. Holt sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $5.98, for a total transaction of $35,880.00. Following the transaction, the director now owns 17,430 shares in the company, valued at $104,231.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David S. Richmond purchased 37,210 shares of Rockwell Medical stock in a transaction that occurred on Wednesday, March 22nd. The shares were bought at an average price of $5.84 per share, for a total transaction of $217,306.40. Following the transaction, the insider now directly owns 176,412 shares of the company’s stock, valued at $1,030,246.08. The disclosure for this purchase can be found here. 15.90% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in RMTI. Vanguard Group Inc. boosted its position in shares of Rockwell Medical by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,990,057 shares of the company’s stock valued at $12,458,000 after buying an additional 93,589 shares in the last quarter. Perritt Capital Management Inc. bought a new position in shares of Rockwell Medical during the fourth quarter valued at about $314,000. Perkins Capital Management Inc. boosted its position in shares of Rockwell Medical by 9.6% in the first quarter. Perkins Capital Management Inc. now owns 485,433 shares of the company’s stock valued at $3,039,000 after buying an additional 42,683 shares in the last quarter. Blue Clay Capital Management LLC bought a new position in shares of Rockwell Medical during the third quarter valued at about $253,000. Finally, Geode Capital Management LLC boosted its position in shares of Rockwell Medical by 9.7% in the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock valued at $2,326,000 after buying an additional 32,964 shares in the last quarter. Institutional investors own 21.14% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

5 Day Chart for NASDAQ:RMTI

Receive News & Ratings for Rockwell Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.